Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease
NCT04436081
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Dementia
- Major Neurocognitive Disorder With Aggressive Behavior
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 50 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eastern Virginia Medical School
- Last updated on ClinicalTrials.gov
- February 16, 2023
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Virginia · 1
- Eastern Virginia Medical School · Norfolk, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.